WealthSource Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

WealthSource Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,049	Closed	-$331K	–	526
2023 Q1	$331K	Buy	1,049 +9	+0.9%	+$2.7K	0.02%	389
2022 Q4	$300K	Sell	1,040 -41	-4%	-$12.5K	0.02%	397
2022 Q3	$313K	Buy	1,081 +359	+50%	+$103K	0.02%	386
2022 Q2	$203K	Buy	+722	New	+$193K	0.01%	487

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WealthSource Partners's VRTX Position: Q2 2023 in Review

WealthSource Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 1,049 shares — an estimated $331K sold.

WealthSource Partners first reported a position in VRTX in Q2 2022 and held it in 4 quarters. The position peaked at $331K in Q1 2023. 1,285 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

WealthSource Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
WealthSource Partners sold 1,049 Vertex Pharmaceuticals shares in Q2 2023, an estimated $331K.
WealthSource Partners first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 4 quarters.
WealthSource Partners's Vertex Pharmaceuticals position peaked at $331K in Q1 2023.
1,285 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on WealthSource Partners's 13F filing for Q2 2023, filed 15 Aug 2023.